相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses
Quazim A. Alayo et al.
SCIENTIFIC REPORTS (2020)
Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved Tolerability
Edward M. Kennedy et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Optimizing oncolytic virotherapy in cancer treatment
Kevin Harrington et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III- IV melanoma
Robert H. Andtbacka et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Tissue-resident memory CD8+ T cells amplify anti-tumor immunity by triggering antigen spreading through dendritic cells
Evelyn Menares et al.
NATURE COMMUNICATIONS (2019)
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments
Kevin C. Barry et al.
NATURE MEDICINE (2018)
Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3- Cell-Mediated Modulation of CD103+ Dendritic Cells
Paul A. Beavis et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Flavia Castro et al.
FRONTIERS IN IMMUNOLOGY (2018)
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Joy Hsu et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL)
Robert Hans Ingemar Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Christopher S. Garris et al.
IMMUNITY (2018)
Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments
Jong W. Yu et al.
PLOS ONE (2018)
The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity
Jan P. Boettcher et al.
TRENDS IN CANCER (2018)
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Suzanne I. S. Mosely et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The pUL37 tegument protein guides alphaherpesvirus retrograde axonal transport to promote neuroinvasion
Alexsia L. Richards et al.
PLOS PATHOGENS (2017)
Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials
Ibrahim Ragab Eissa et al.
Frontiers in Oncology (2017)
QuPath: Open source software for digital pathology image analysis
Peter Bankhead et al.
SCIENTIFIC REPORTS (2017)
Local Delivery of OncoVEXmGM-CSF Generates Systemic AntitumorImmuneResponses Enhanced by Cytotoxic T-Lymphocyte-Associated Protein Blockade
Achim K. Moesta et al.
CLINICAL CANCER RESEARCH (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy
Stefani Spranger et al.
CANCER CELL (2017)
The Herpes Simplex Virus Neurovirulence Factor γ34.5: Revealing Virus-Host Interactions
Douglas R. Wilcox et al.
PLOS PATHOGENS (2016)
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
Hasan Rehman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
The S228P Mutation Prevents in Vivo and in Vitro IgG4 Fab-arm Exchange as Demonstrated using a Combination of Novel Quantitative Immunoassays and Physiological Matrix Preparation
John-Paul Silva et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells
Jake Chng et al.
MABS (2015)
Use of miRNA Response Sequences to Block Off-target Replication and Increase the Safety of an Unattenuated, Glioblastoma-targeted Oncolytic HSV
Lucia Mazzacurati et al.
MOLECULAR THERAPY (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Oncolytic viruses: a new class of immunotherapy drugs
Howard L. Kaufman et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Emergence of a Stage-Dependent Human Liver Disease Signature with Directed Differentiation of Alpha-1 Antitrypsin-Deficient iPS Cells
Andrew A. Wilson et al.
STEM CELL REPORTS (2015)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Development and Function of Dendritic Cell Subsets
Alexander Mildner et al.
IMMUNITY (2014)
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Dmitriy Zamarin et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Maximal T Cell-Mediated Antitumor Responses Rely upon CCR5 Expression in Both CD4+ and CD8+ T Cells
Alicia Gonzalez-Martin et al.
CANCER RESEARCH (2011)
NK Cell-Depleting Anti-Asialo GM1 Antibody Exhibits a Lethal Off-Target Effect on Basophils In Vivo
Hideto Nishikado et al.
JOURNAL OF IMMUNOLOGY (2011)
Ipilimumab
Vernon K. Sondak et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells
Mingjie Li et al.
JOURNAL OF NEUROSCIENCE METHODS (2010)
A Double Mutation in Glycoprotein gB Compensates for Ineffective gD-Dependent Initiation of Herpes Simplex Virus Type 1 Infection
Hiroaki Uchida et al.
JOURNAL OF VIROLOGY (2010)
Construction and characterization of bacterial artificial chromosomes containing HSV-1 strains 17 and KOS
William W. Gierasch et al.
JOURNAL OF VIROLOGICAL METHODS (2006)
Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus
H Kambara et al.
CANCER RESEARCH (2005)
Functional expression of the chemokine receptor CCR5 on virus epitope-specific memory and effector CD8(+) T cells
K Fukada et al.
JOURNAL OF IMMUNOLOGY (2002)
Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing
T Todo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
分享论文
